HAVN Life: Is the Shroom Boom the Future of Mental Health?
HAVN Life Sciences Inc (OTCMKTS:HAVLF) is a brand new public company with a mission to be the future of psychedelic medicine. The shroom boom is in full effect, so we sat down to talk about how HAVN is differentiating itself within this emerging space.
Former Aphria Inc (NASDAQ:APHA) CEO, former Jamieson Wellness Inc (TSE:JWEL) CEO, and now HAVN Life Sciences Executive Chairman Vic Neufeld has vast experience in both the health & wellness and once-illegal drug space. We sat down with Vic to discuss his new tenure and his thoughts on the psychedelic market.
Mother nature is truly a source of personal health treatments – that’s not synthetic. Plant derived (medicines) brings science to the forefront and moves the needle. – Vic Neufeld
We discuss the key compounds HAVN is using which elicit the best response for illnesses such as PTSD, anxiety, depression, addiction, and more… We also find out about the company’s natural health products, using non-magic mushroom, custom formulations to support healthy bodily functions.
Watch this exclusive interview to find out the latest from HAVN Life Sciences and psychedelic medicines.
Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.
Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.
Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.